Status:
COMPLETED
Study of ACE-536 in Healthy Postmenopausal Women
Lead Sponsor:
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Conditions:
Anemia
Eligibility:
FEMALE
45-75 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to find out whether ACE-536 can be safely given to patients. This study will also look to see if ACE-536 increases red blood cells, the cells that carry oxygen in the body...
Eligibility Criteria
Inclusion
- Key
- Postmenopausal women
- Body Mass Index (BMI) of 20 - 32 kg/m2.
- Key
Exclusion
- History of hypertension
- Subject has received any erythropoiesis stimulating agents (e.g., Epogen, Procrit, Aranesp, etc.) within 6 months prior to Day 1
- History of clinically significant cardiac, endocrine, hematologic, hepatic, immune, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other disease
- Surgery within 3 months (other than minor cosmetic surgery or minor dental procedures)
- Subject has received treatment with another investigational drug, or approved therapy for investigational use within 1 month prior to Day 1, or if the half-life of the previous product is known, within 5 times the half-life prior to Day 1, whichever is longer
Key Trial Info
Start Date :
September 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01432717
Start Date
September 1 2011
End Date
October 1 2012
Last Update
November 7 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Acceleron Investigative Site
Tempe, Arizona, United States